



REMARKS

Reconsideration and allowance are respectfully requested.

Claims 28-41 are now pending, with Claim 28 being the sole independent claim.

Claims 1-27 have been canceled without prejudice to or disclaimer of the subject matter recited therein.

Claims 28-41 have been added. Support for the sequence identities recited in Claims 24-26 is found at least in the paragraph beginning on line 35 of page 5 of the specification. Support for the use of the term "recombinant" in Claims 35 and 37-41 is found at least in the paragraph beginning on line 10 of page 10 of the specification. Support for Claims 38-40 are found at least in Examples 4-5, pages 18-21 of the specification. No new matter has been added.

The specification has been amended at two locations to remove reference to the following URL: www.ncbi.nlm.nih.gov/BLAST/.

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement in the Office Action mailed August 22, 2003, Applicants hereby elect, without traverse, Group I (drawn to a polynucleotide, nucleic acid constructs and a method of using the polynucleotide) and the polynucleotide of SEQ ID NO:5 (the polynucleotide of SEQ ID NO:5 codes for the polypeptide of SEQ ID NO:6). Applicants believe new claims 28-41 fall into Group I.

Please charge any fees or credit any overpayment of fees which are required in connection herewith to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

In view of the foregoing, allowance of the above-referenced application is respectfully requested.

Respectfully submitted,

J. KENNETH JOUNG
ATTORNEY FOR APPLICANTS
REGISTRATION NO. 41,881
TELEPHONE: 302-992-4929
FACSIMILE: 302-892-1026

Dated: 22 October 2003